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Abstract
Background—Many of the neurobehavioral effects of ethanol are mediated by inhibition of
excitatory N-methyl-D-aspartate (NMDA) and enhancement of inhibitory γ-amino-butyric-acid
(GABA) receptor systems. There is growing interest in drugs that alter these systems as potential
medications for problems associated with alcoholism. The drug riluzole, approved for treatment of
amyotrophic lateral sclerosis (ALS), inhibits NMDA and enhances GABAA receptor system activity.
This study was designed to determine the preclinical efficacy of riluzole to modulate ethanol self-
administration and withdrawal.
Methods—Male C57BL/6J mice were trained to lever press on a concurrent fixed-ratio 1 schedule
of ethanol (10% v/v) versus water reinforcement during daily 16-hour sessions. Riluzole (1 to 40
mg/kg, IP) was evaluated on ethanol self-administration after acute and chronic (2 week) treatment.
To determine if riluzole influences ethanol withdrawal-associated seizures, mice were fed an ethanol-
containing or control liquid diet for 18 days. The effects of a single injection of riluzole (30 mg/kg)
were examined on handling-induced convulsions after ethanol withdrawal.
Results—Acute riluzole (30 and 40 mg/kg) reduced ethanol self-administration during the first 4
hours of the session, which corresponds to the known pharmacokinetics of this drug. Ethanol self-
administration was also reduced by riluzole after chronic treatment. Riluzole (30 mg/kg) significantly
decreased the severity of ethanol-induced convulsions 2 hours after ethanol withdrawal.
Conclusions—These results demonstrate that riluzole decreases ethanol self-administration and
may reduce ethanol withdrawal severity in mice. Thus, riluzole may have utility in the treatment of
problems associated with alcoholism.
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Alcoholism is a complex neurobehavioral disorder that is characterized in part by excessive
consumption of ethanol and by the development of physical dependence. Many of the
neurobiological and behavioral effects of ethanol are mediated by excitatory NMDA and
inhibitory GABAA receptor systems (for reviews see Davis and Wu, 2001; Grant and Lovinger,
1995; Koob et al., 1998; Nevo and Hamon, 1995). For example, preclinical studies have shown
that GABAA and NMDA receptor systems modulate ethanol drinking (Bienkowski et al.,
2001; June et al., 1992), reinforcement (Hodge et al., 1996), reward (Chester and Cunningham,
1999), drug discrimination (Besheer et al., 2003; Grant et al., 1991; Hodge and Cox, 1998),
tolerance (Khanna et al., 1991; Mihic et al., 1992), dependence (Morrisett et al., 1990; Morrow
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et al., 1994), and relapse (Nie and Janak, 2003). Given the involvement of GABAergic and
NMDA/glutamatergic systems in a variety of ethanol's neurobiological and behavioral effects,
there is growing interest in these systems as potential therapeutic targets in the pharmacological
treatment of problems associated with alcoholism (Anton, 2001; Davis and Wu, 2001; Nevo
and Hamon, 1995). One efficient strategy that might be used to identify candidate medications
for treatment of alcoholism is to use preclinical animal models to evaluate the potential of FDA
approved medications with mechanism(s) of action that are known to underlie the
neurobehavioral effects of ethanol.
The drug riluzole (2-amino-6-trifluoromethoxy benzothiazole), which is presently an approved
medication for the treatment of amyotrophic lateral sclerosis (ALS) (Wagner and Landis,
1997), appears to be one such candidate. That is, riluzole inhibits the presynaptic release of
glutamate (Jehle et al., 2000; Martin et al., 1993) and may act postsynaptically to interfere with
NMDA receptor function (reviewed by Doble, 1996). Evidence also indicates that riluzole
decreases GABA uptake (Mantz et al., 1994) and potentiates function of postsynaptic
GABAA receptors (He et al., 2002). In vivo, riluzole has neuroprotective (Debono et al.,
1993; Malgouris et al., 1989; Pratt et al., 1992), anticonvulsant (Mizoule et al., 1985; Romettino
et al., 1991), anxiolytic-like (Munro et al., 2007), and sedative properties (Mantz et al., 1992)
that are consistent with a decrease in CNS excitability via inhibition of NMDA and
enhancement of GABAA receptor activity.
Riluzole also appears to have another mechanism of action which may indirectly result in
inhibition of CNS excitation. Noh and colleagues (2000) found riluzole to be an effective and
direct inhibitor of protein kinase C (PKC). PKC is a family of kinases that regulates a variety
of neuronal functions including ion channel activity, neurotransmitter release, receptor
desensitization, and differentiation (Tanaka and Nishizuka, 1994). PKC has been shown to
positively modulate glutamate channels, as well as sodium and chloride channels (Shearman
et al., 1989). Moreover, the finding that riluzole inhibits PKC presents the possibility that
riluzole-induced suppression of glutamate release may occur via an indirect mechanism.
Previous work from our laboratory has shown that mice lacking the epsilon isoform of PKC
(PKCε) show decreased ethanol self-administration (Hodge et al., 1999; Olive et al., 2000),
greater sensitivity to ethanol's sedative effects (Hodge et al., 1999), reduced anxiety-like
behavior (Hodge et al., 2002), and exhibit diminished ethanol-induced withdrawal seizures
(Olive et al., 2001).
Given that riluzole influences glutamate and GABA functioning, and inhibits PKC, the effects
of riluzole on ethanol self-administration were tested in inbred C57BL/6J mice, with the
prediction that riluzole pretreatment would reduce ethanol self-administration. The pattern of
self-administration behavior across the 16-hour session was examined in 4-hour intervals in
an effort to relate behavior with the known kinetics of riluzole after IP administration in mice,
which shows a dual peak in brain levels at 20 and 80 minutes and is then significantly reduced
by 4 hours (Hockly et al., 2006). Further, given riluzole's general suppressant effect on the
central nervous system and anticonvulsant properties, suppression of ethanol withdrawal
seizures was also predicted. Because riluzole is already approved for human use, reductions
in ethanol self-administration and withdrawal seizures may make this drug a viable therapeutic
for the treatment of alcohol use disorders.
Method
Animals
Male mice (C57BL/6J; Jackson Laboratories, Bar Harbor, ME) housed in standard Plexiglas
cages with at most 4 mice per cage were used in the ethanol self-administration study (n = 12)
and the ethanol withdrawal assessments (n = 36). Food and water were continuously available
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except during self-administration lever press training and the ethanol withdrawal study (see
later). The colony room was maintained on a 12-hour light/dark cycle with lights on at 07:00
hours.
Apparatus
Twelve Plexiglas operant chambers (Med Associates, Georgia, VT) measuring 15.9 × 14 ×
12.7 cm with stainless steel grid floors were used. Each chamber was housed in a sound-
attenuating cubicle equipped with a fan that provided ventilation and masked external noise.
The left and right wall of each chamber contained 1 ultra-sensitive stainless steel response lever
and a recessed liquid well. One lever press activated a syringe pump that was attached to that
liquid well and delivered 0.01 ml of solution. A stimulus light was located above each response
lever and was activated each time a reinforcer was delivered. The chambers were illuminated
by a house light that was on during the first and last 2 hours of each daily 16-hour session. The
chambers were controlled using a computer interface and PC software (Med Associates).
Ethanol Self-Administration
Training Procedures—Operant ethanol self-administration was measured during 16-hour
sessions (between 17:00 and 09:00 hours). To correspond with the 12-hour light/dark cycle in
the animal colony room, the chambers were illuminated via the house light from 17:00 to 19:00
and 07:00 to 09:00 hours. On the first 2 days of training, mice were weighed and individually
placed into a test chamber for overnight 16-hour training sessions to establish reliable lever
pressing behavior. Before each of these sessions, water was removed from the home cages 24
hours before the first training session and returned for 2 hours following each training session.
During these sessions, both levers were active on a concurrent fixed-ratio 1 (CONC FR1 FR1)
schedule with 10% sucrose and water presented as the reinforcer. That is, one lever response
resulted in the presentation of 0.01 ml of the solution paired with that lever. On the following
days, animals were trained to orally self-administer ethanol using a sucrose substitution
procedure (Hodge et al., 1995; Samson, 1986, 1987). Briefly, the FR1 contingency was in place
and ethanol was gradually added to the 10% sucrose solution and the sucrose was gradually
faded out so that 10% ethanol maintained lever pressing. The mice experienced 4 training
sessions a week (Monday through Thursday).
Acute Riluzole Administration—At the beginning of riluzole testing, the mice had
approximately 10 months of experience self-administering ethanol and weighed an average of
33.84 ± 0.42 g. The mice had been previously used in another study (2 months earlier) and as
such were not drug-naïve. Test sessions were conducted on Tuesday and Thursday of each
week. For each 16-hour test session, mice were administered riluzole (0, 1, 10, 30, and 40 mg/
kg, IP) and immediately placed in the operant chambers. Riluzole was administered according
to a Latin-Square design with the exception that the highest dose (40 mg/kg) was tested last in
all animals. Each mouse received a single injection of each dose.
Chronic Riluzole Administration—One week after the final acute riluzole test, mice were
divided into 2 groups: control and riluzole, and received daily vehicle (n = 6) or 30 mg/kg
riluzole (n = 6) injections, respectively. To ensure that the 2 groups did not differ on baseline
ethanol and water responding, the hourly ethanol and water responses for the 2 days before the
beginning of the acute riluzole assessments were averaged and compared. No significant main
effects or interactions were observed. For the control group, total ethanol and water responses
were 237.92 ± 10.32 and 86.17 ± 18.55, respectively. For the Riluzole group, total ethanol and
water responses were 208.75 ± 27.19 and 83.08 ± 18.62, respectively. Monday through
Thursday self-administration training sessions continued and injections were administered
immediately before the sessions. On non-training days (Friday through Sunday), mice were
injected and returned to the home cage. This injection protocol continued for 2 weeks.
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Male C57BL/6J mice were maintained on a modified high-protein Lieber-DeCarli liquid
control diet (n = 16) or ethanol diet (n = 20; Dyets Inc., Bethlehem, PA) as the sole source of
nutrients and fluids for 18 days. Although C57BL/6 mice are not as sensitive to ethanol
withdrawal seizures as other mouse strains (Crabbe et al., 1983), this mouse strain was used
to maintain consistency with the self-administration studies. Moreover, the liquid diet
procedure has been shown to produce 75% mortality in DBA/2J mice, which is an ethanol
withdrawal sensitive strain (Goldstein and Arnold, 1976). In the ethanol group, the ethanol
concentration in the diet was 2.4% for the first 2 days, and was increased to 4.8% for the
remaining 16 days. Each day the mice were weighed and the amount of fluid consumed was
recorded. On day 18, the liquid diet was removed 30 minutes after the onset of the light cycle
(07:30 hours) and the mice were injected with riluzole (30 mg/kg, IP) or vehicle. Mice were
evaluated at 2, 4, 6, and 8 hours following the removal of the diet for withdrawal-induced
seizures according to a handling-induced convulsion (HIC) scale (modified from Goldstein,
1972b, as previously reported, Olive et al., 2001; see Table 1). During these seizure
assessments, each mouse was lifted by the tail and an observer blind to the treatment conditions
of the mice evaluated the severity of the seizures.
Drugs
For self-administration, ethanol (95% w/v) was diluted in distilled water to a concentration of
10% (v/v). Riluzole (Sigma, St Louis, MO) was suspended in cyclodextrin (20% w/v) solution
which was the vehicle. Riluzole and the cyclodextrin vehicle were injected IP at a volume of
0.01 ml/g of body weight.
Data Analysis
Ethanol intake (g/kg) was estimated from body weight and the number of reinforcers delivered.
For the acute riluzole treatment self-administration study, total ethanol intake was analyzed by
1-way repeated measures analysis of variance (RM ANOVA). Total session self-administration
and the pattern of responding in 4-hour intervals were analyzed by 2-way RM ANOVA. For
the chronic riluzole experiment, self-administration was averaged for each week of the 2 weeks
of treatment (i.e., week 1 and week 2). For these studies, total session self-administration and
the pattern of responding in 4-hour intervals for week 1 and week 2 were examined by a mixed
factors ANOVA, with lever as the within subject factor and treatment (vehicle or riluzole) as
the between subject factor. For the withdrawal seizure assessment study, a 3-way mixed factor
ANOVA was used. Two-way ANOVAs were used to further explore significant interactions.
Post hoc comparisons were conducted using Tukey's procedure.
Results
Ethanol Self-Administration
Acute Riluzole Administration—Riluzole significantly reduced total ethanol intake
during the 16-hour sessions [F(4,39) = 3.79, p = 0.01; vehicle: 5.34 ± 0.7; 1 mg/kg: 5.03 ±
0.54; 10 mg/kg: 5.58 ± 0.53; 30 mg/kg: 4.10 ± 0.44; 40 mg/kg 3.94 ± 0.36 g/kg]; however,
intake at each riluzole dose did not differ significantly from vehicle treatment. Responses on
the ethanol and water levers for the 16-hour self-administration session are shown in Fig. 1A.
There was a significant main effect of riluzole dose [F(4,36) = 7.66, p < 0.001; vehicle vs. 40
mg/kg], and a significant main effect of lever [F(1,9) = 44.17, p < 0.001]. The interaction was
not significant.
In an effort to relate self-administration to the known pharmacokinetics of riluzole, ethanol
and water responses were examined in 4-hour intervals (see Table 2). Examination of the first
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4 hours of the self-administration session showed a significant main effect of riluzole dose [F
(4,36) = 11.53, p < 0.001], a significant main effect of lever [F(1,9) = 27.45, p < 0.001], and
a significant interaction [F(4,36) = 6.55, p < 0.001; Fig. 1B]. Ethanol responding was
significantly reduced by 30 and 40 mg/kg riluzole, probabilities <0.02. Water responding was
not significantly altered by riluzole treatment but visual inspection of the data suggest a trend
toward a reduction. For the other time intervals examined (8, 12, and 16 h), significant main
effects of lever were observed with greater ethanol responses than water responses [8 h: F(1,9)
= 39.52, p < 0.001; 12 h: F(1,9) = 22.57, p < 0.001; 16 h: F(1,9) = 24.12, p < 0.001]. Riluzole
treatment did not alter responding at any of these time points (see Table 2).
Chronic Riluzole Administration—Total ethanol intake during the 16-hour sessions for
the 2 weeks of chronic riluzole treatment did not differ (vehicle: 5.67 ± 0.24 g/kg; riluzole:
4.41 ± 0.66 g/kg). In order to determine if the chronic riluzole pretreatment regimen altered
responding over time, the average of the ethanol and water responses from the first week of
the treatment regimen were compared to the average of the ethanol and water responses from
the second week of the treatment regimen for each group. Total ethanol and water lever
responses during the 16-hour self-administration sessions on week 1 and week 2 of riluzole
treatment are shown in Fig. 1C. For week 1 and week 2 significant main effects of lever were
observed [week 1: F(1, 10) = 30.83, p < 0.001; week 2: F(1,10) = 43.34, p < 0.001], with greater
responding on the ethanol lever. No significant main effects of riluzole dose were observed.
As in the acute riluzole study, self-administration was examined in 4-hour intervals. As shown
in Fig. 1D, during the first 4 hour of the self-administration session, ethanol responding was
significantly reduced by riluzole during week 1 [F(1,10) = 5.65, p = 0.04) and week 2 (F(1,10)
= 10.94, p = 0.008]. A significant main effect of lever was also evident at both weeks [week
1: F(1,10) = 28.98 p < 0.001; week 2: F(1,10) = 45.31, p < 0.001]. A significant lever by
treatment interaction was also present at both weeks [week 1: F(1,10) = 5.07, p = 0.048; week
2: F(1,10) = 5.07, p = 0.048]. During both weeks, riluzole treatment significantly reduced
ethanol responses (probabilities <0.01), and did not alter water responses. Ethanol and water
responses at the other time intervals examined (8, 12, and 16 hours) for weeks 1 and 2 are
shown in Table 3. Main effects of lever were observed at each time interval with greater ethanol
responses than water responses [week 1 to 8 hours: F(1,10) = 16.50, p = 0.002; 12 hours: F
(1,10) = 44.30, p < 0.001; 16 hours: F(1,10) = 10.79, p = 0.008; week 2 to 8 hours: F(1,10) =
28.42, p < 0.001; 12 hours: F(1,10) = 49.59, p < 0.001; 16 hours: F(1,10) = 15.72, p = 0.003].
Riluzole treatment did not alter responding at any of these time points (see Table 3).
Ethanol Withdrawal Seizures
Average ethanol intake for the first 2 days of liquid diet (2.4%) was 15.65 ± 0.28 g/kg. Ethanol
intake was consistent across the 16 days of exposure to 4.8% ethanol (day 1 of 4.8%: 22.51 ±
0.42 g/kg; day 16 of 4.8% 22.4 ± 0.42 g/kg). The 2 groups (vehicle and riluzole) did not differ
on ethanol intake (g/kg per day) across the liquid diet exposure. On the final day of liquid diet
exposure ethanol intake for the vehicle group was 22.57 ± 0.7 g/kg and for the riluzole group
was 22.26 ± 0.55 g/kg. The time course of withdrawal severity is shown in Fig. 2. The average
HIC score during withdrawal was significantly higher for the ethanol-fed mice [F(1,32) = 6.88,
p = 0.01] than the control-fed mice. A 3-way mixed design ANOVA showed significant
interactions between time and diet type [F(3,96) = 3.02, p = 0.03], and time, diet, and riluzole
treatment [F(3,96) = 2.95, p = 0.04]. In the ethanol-fed mice, a subsequent 2-way repeated
measures ANOVA showed a significant interaction between time and riluzole treatment [F
(3,46) = 3.41, p = 0.03], with a significant riluzole-induced reduction in HIC scores 2 hours
following diet removal, p = 0.01. Area under the withdrawal curve after ethanol removal did
not differ after riluzole treatment (mean ± SEM: vehicle—11.33 ± 3.12; riluzole—10.20 ±
3.55). In the control-fed mice, a reduction in muscle tone and ataxia was observed after riluzole
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treatment which likely contributed to a significant main effect of riluzole treatment [two-way
RM ANOVA: F(1,17) = 8.05, p = 0.01], with overall lower HIC scores after riluzole treatment,
p = 0.01. This effect was likely due to the lack of any withdrawal-like behaviors after riluzole
treatment (i.e., scores of 0).
Discussion
The goal of this study was to conduct a preclinical evaluation of the drug riluzole for potential
use as a therapeutic agent to treat problems associated with alcoholism. First, the effects of
riluzole on ethanol-reinforced responding by C57BL/6J mice were evaluated after acute and
chronic treatment to assess the efficacy of riluzole in reducing the maintenance of ethanol self-
administration. Second, the ability of acute riluzole treatment to blunt ethanol-induced
withdrawal seizures was also evaluated.
Ethanol Self-Administration
In general, riluzole did not produce significant changes in ethanol self-administration when
total responding during the 16-hour session was examined. In healthy human subjects plasma
levels of riluzole peak at approximately 1 to 2 hours after oral administration, gradually decline
by 4 hours and remain at stable levels until about 12 hours after administration (Le Liboux et
al., 1999; Schwenkreis et al., 2000). The pharmacokinetic profile has not been extensively
examined in rodents. However, after IP administration of riluzole (30 mg/kg) in the mouse,
concentration of the compound in plasma peaks at 20 minutes and in brain peaks at 20 to 80
minutes after injection and both levels are significantly decreased by 4 hours (Hockly et al.,
2006). This pattern of drug clearance suggests that riluzole may differentially affect self-
administration behavior throughout the 16-hour session. As such, self-administration behavior
was examined during the entire 16 hour session and in shorter time intervals (4 hours). During
the initial 4 hours of the self-administration session, ethanol responses were significantly
reduced by the 2 highest riluzole doses tested (30 and 40 mg/kg). Further, riluzole did not affect
ethanol self-administration at any other time interval examined. This pattern of results suggests
that the reduction in ethanol self-administration during the early part of the session most likely
corresponds to peak riluzole levels.
Chronic treatment with riluzole produced similar reductions in ethanol self-administration as
acute treatment. That is, overall ethanol and water responding across the 16-hour session
showed no change. However, examination of responding in 4-hour intervals showed a riluzole-
induced reduction in ethanol self-administration during the first 4 hours of the session. Further,
week 1 and week 2 of riluzole treatment produced similar reductions in ethanol self-
administration during the first 4 hours of the session, suggesting no tolerance to riluzole's
effects. Further, this suggests that the compound is efficacious at reducing ethanol self-
administration after repeated administration, which would be a desirable profile for a potential
therapeutic agent.
The behavioral mechanism(s) by which riluzole reduced ethanol self-administration is not
clear. Riluzole does not produce stimulus properties similar to ethanol (Hundt et al., 1998),
which suggests that the riluzole-induced reductions in ethanol responding are not likely a result
of drug substitution. However, riluzole has been shown to have rewarding properties as
measured by conditioned place preference procedures (Tzschentke and Schmidt, 1998),
suggesting that the drug may produce distinct stimulus properties itself. Indeed, in healthy
human subjects, riluzole has been shown to potentiate the subjective properties of amphetamine
and produce some amphetamine-like subjective effects (Sofuoglu et al., 2008). Thus, while
not producing “ethanol-like” stimulus effects per se riluzole may have produced a distinct
subjective or rewarding state that competed/interfered with motivation to self-administer
ethanol. Potential abuse liability of riluzole needs to be examined in future studies. Another
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possible behavioral explanation for the reduction in ethanol self-administration is that riluzole
produced a motor impairment. Indeed, riluzole has been shown to decrease spontaneous
locomotor activity in naïve rodents (Itzhak and Martin, 2000; Kretschmer et al., 1998). In both
the acute study and the chronic treatment study, water responses (total session and 4-hour
intervals) were unaffected by riluzole treatment. Responding on an alternate lever (i.e., water
lever) typically serves as an index of non-specific motor effects. Thus, the absence of a
reduction in water lever responses would make a riluzole-induced motor impairment
explanation less likely; however, some issues are raised regarding interpretation of the lack of
a riluzole effect on water responses. First, response rate on the water lever was relatively low,
which makes it difficult to detect a statistically significant reduction. Second, in the acute study,
riluzole produced a greater percent decrease in responding on the water lever than the ethanol
lever at 30 and 40 mg/kg, suggesting the low baseline responding did in fact contribute to the
lack of statistical significance and a motor reduction may indeed have contributed to the
reduction in ethanol responses. Interestingly, however, this was not evident in the chronic
riluzole administration study. Previous work has found that mice with ethanol self-
administration experience similar to that in the present study are less sensitive to the sedative
properties of GABAergic modulation than ethanol-inexperienced mice (Besheer et al., 2004).
Thus, given that riluzole has been shown to produce motor impairments in ethanol naïve rodents
the effects may not be evident in animals with a history of ethanol self-administration.
However, given that the possibility of a motor impairment was not tested directly in these mice
this explanation cannot be entirely dismissed.
The riluzole-induced reduction in ethanol self-administration is consistent with studies in
which modulators of NMDA/glutamatergic (Bienkowski et al., 1999; Piasecki et al., 1998;
Rassnick et al., 1992) and GABAergic systems (Boyle et al., 1993; Ford et al., 2005; Harvey
et al., 2002; Hodge et al., 1996; Maccioni et al., 2005; Smith et al., 1992) reduce ethanol self-
administration. Further, reductions in ethanol intake using a two-bottle drinking procedure
(Besheer et al., 2006) and ethanol self-administration using a similar 16-hour self-
administration procedure have been observed in mice lacking PKCε (Olive et al., 2000).
Importantly, the general inhibition of PKC by riluzole may have altered sensitivity to ethanol.
For example, mice lacking PKCε are more sensitive to the behavioral and biochemical effects
of ethanol than wildtype littermates (Hodge et al., 1999).
Ethanol Withdrawal Seizures
Riluzole has anticonvulsant properties and is effective at reducing seizures induced by
excitatory amino acids and GABA antagonists (e.g., bicuculline; see Doble, 1996). Riluzole
has been shown to reduce the intensity of the withdrawal syndrome (jumping, paw tremors,
and body shakes) in morphine-dependent mice (Sepulveda et al., 1999); but had no effect on
convulsions induced by an acute cocaine injection (Brackett et al., 2000). This could suggest
differential efficacy of riluzole's anticonvulsive effects after chronic and acute drug exposure;
however, this suggestion will clearly need further evaluation.
Seizures induced by ethanol withdrawal are generally a result of hyperexcitability in the central
nervous system due to changes in GABAergic and glutamatergic systems (Littleton, 1998).
Benzodiazepines and other positive modulators of GABAA receptors are commonly used in
the suppression of ethanol withdrawal seizures (Goldstein, 1972a; Nutt et al., 1989; Romach
and Sellers, 1991); however, NMDA antagonists also show efficacy in attenuating seizures
(Grant et al., 1990; Kotlinska and Liljequist, 1996). In the present work, riluzole (30 mg/kg)
reduced the severity of HICs during ethanol withdrawal. Interestingly, the blunting of ethanol
withdrawal seizures by riluzole was only evident during the first 2 hours of session, which
likely parallels peak riluzole levels as previously discussed. Further, it is of interest to note that
the control-fed (i.e., ethanol-naïve) mice showed ataxia and reduced muscle tone during these
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observations; loss of righting reflex was not evaluated in these animals, however, previous
work has shown that riluzole can induce a loss of righting reflex (Irifune et al., 2007; Mantz
et al., 1992). Overall, the ability of riluzole to inhibit ethanol withdrawal symptoms is consistent
with its actions on GABA and NMDA systems.
In this study, the severity of ethanol withdrawal seizures in vehicle treated C57BL/6J mice
peaked 2-hour after removal of the ethanol-containing liquid diet. HIC scores at this time point
were comparable to what we have previously observed in mice of a hybrid 129SvJae × C57BL/
6J genetic background under similar experimental conditions (Olive et al., 2000). However,
seizure severity did not increase as a function of time after ethanol removal, which is in contrast
to published literature showing the emergence of withdrawal-induced seizures 4 to 8 hours
after diet removal (Chan et al., 1981; Goldstein and Arnold, 1976; Olive et al., 2000). One
potential explanation for this result was the use of C57BL/6 mice, which are relatively
insensitive to ethanol withdrawal seizures (Crabbe et al., 1983). Another explanation is that
testing may have been conducted on the descending limb of the HIC curve. This suggests that
liquid diet consumption peaked during the early phase of the dark cycle (Hunter et al., 1975;
Jelic et al., 1998), which resulted in a progression of the withdrawal syndrome prior to
measurement. Further, the area under the withdrawal curve did not differ between the 2 ethanol
groups (e.g., withdrawal time course was shifted in the 2 groups) supporting the suggestion
that ethanol diet exposed animals were undergoing withdrawal prior to measurement. It will
be important to determine the efficacy of riluzole to inhibit ethanol withdrawal seizures in
seizure prone mice (i.e., DBA/2J) or under different treatment conditions that allow precise
temporal regulation of ethanol exposure and withdrawal.
Another topic that merits discussion is that blood ethanol levels were not evaluated when the
ethanol liquid diet was removed from the home cage. Blood samples were not collected at this
time due to concerns that procedural stress may interfere with the study. Thus, the treatment
groups (vehicle or riluzole) were equated and assigned based on ethanol intake on the final 24-
hour and across the liquid diet exposure. While there is no reason to expect a different pattern
of liquid diet consumption between the groups (i.e., prior to riluzole treatment), there is the
possibility that the riluzole-treated group had lower blood ethanol levels at the time of riluzole
administration, which may have contributed to the drug effect.
Conclusions
The results of the present work show that riluzole can selectively reduce ethanol self-
administration after acute and chronic administration, and reduce the severity of ethanol
withdrawal seizures. Based on this initial study, additional preclinical research is warranted to
further assess whether riluzole could be potentially useful as a clinical therapeutic for alcohol
use disorders. Although it is unclear if riluzole would be more efficacious than current FDA
approved medications for alcohol use disorders, the drug's broad spectrum of effects on
glutamate, GABA, and PKC make it an interesting candidate for further study. It will also be
important to evaluate potential interactions between riluzole and ethanol, assess effects of
riluzole on relapse-like behavior, and determine the side effect profile (i.e., potential motor
inhibition) and efficacy of riluzole treatment after a history of prolonged ethanol exposure.
Overall, the findings of the present work suggest that riluzole, a drug presently used in the
treatment of ALS, may have potential utility in the treatment of problems associated with
chronic drinking and ethanol withdrawal symptoms.
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(A) Mean (±SEM) responses on the ethanol (10% v/v) and water levers during the 16-hour
self-administration session after acute riluzole treatment (N = 12). (B) Mean (±SEM) responses
on the ethanol and water levers during the first 4-hour interval (0–4 hours) of the 16-hour
session after acute riluzole treatment (N = 12). (C) Mean (±SEM) responses on the ethanol
(10% v/v) and water levers during the 16-hour self-administration session after the first week
(week 1) and the second week (week 2) of chronic riluzole (30 mg/kg) treatment. (N = 6/group).
(D) Mean (±SEM) responses on the ethanol and water levers during the first 4-hour interval
(0–4 hours) of the 16-hour session during week 1 and week 2 after chronic riluzole (30 mg/
kg) treatment (N = 6/group). *Indicates significant difference from vehicle (Tukey, p < 0.05).
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Mean (±SEM) Handling-Induced Convulsion (HIC) score in mice maintained on control or
ethanol (4.8% v/v)-containing liquid diet. Liquid diet was removed at 07:30 hour and all mice
were administered vehicle or 30 mg/kg riluzole. Assessments were made 2, 4, 6, and 8 hours
after diet removal. Control/Vehicle (n = 9); Control/Riluzole (n = 10); Ethanol/Vehicle (n =
8); Ethanol/Riluzole (n = 10). *Indicates significant difference from Ethanol/Vehicle (Tukey,
p < 0.05).
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Table 1
Handling-Induced Convulsions Scale Used in the Present Study
Score Description
7 Severe tonic–clonic convulsions prior to tail lift with rapid onset and long duration
6 Severe tonic–clonic convulsion when lifted by tail with rapid onset and long duration
5 Tonic–clonic convulsion when lifted by tail; onset delayed by 1–2 s
4 Tonic convulsion when lifted by tail
3 Convulsion when lifted by tail and after spin
2 No convulsion when lifted by tail; tonic convulsion after spin
1 No convulsion or facial grimace when lifted by the tail; facial grimace after spin
0 No convulsion or facial grimace
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Table 3
Self-Administration (Responses) in 4-Hour Intervals After Chronic Riluzole Treatment
Week 1 Week 2
Riluzole dose (mg/kg, IP) Riluzole dose (mg/kg, IP)
0 30 0 30
0–4 hours
 Ethanol lever 77.75 ± 7.04 47.68 ± 8.84* 86.32 ± 7.01 47.57 ± 11.84*
 Water lever 7.46 ± 3.01 18.85 ± 7.97 9.29 ± 3.24 9.17 ± 4.03
4–8 hours
 Ethanol lever 78.58 ± 2.83 65.99 ± 9.98 78.75 ± 4.42 58.13 ± 10.99
 Water lever 7.75 ± 1.78 37.06 ± 15.99 9.67 ± 2.07 23.75 ± 11.27
8–12 hours
 Ethanol lever 43.08 ± 4.24 32.60 ± 6.65 41.33 ± 4.80 36.29 ± 4.61
 Water lever 6.13 ± 1.44 8.99 ± 3.13 6.75 ± 1.78 11.21 ± 3.87
12–16 hours
 Ethanol lever 55.88 ± 5.90 59.94 ± 4.52 62.29 ± 5.95 55.67 ± 7.64
 Water lever 40.96 ± 16.04 17.93 ± 6.70 32.33 ± 12.93 16.25 ± 5.76
*
Indicates significant difference from 0 (Tukey, p < 0.05).
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